Molecular classification of aggressive lymphomas—past, present, future

Aggressive large B-cell lymphomas (LBCLs) represent a frequent but clinically and molecularly heterogeneous group of tumors. Technological advances over the last decades prompted development different classification schemas to either sharpen diagnoses, dissect molecular heterogeneity, predict outcome, or identify rational treatment targets. Despite increased diagnostic precision noticeably improved understanding these lymphomas, clinical perspectives patients largely remain unchanged. Recently, finished comprehensive genomic studies discovered genetically defined LBCL subtypes that provide insight into lymphomagenesis, suggest therapies with hope generating patient-tailored treatments perspective for in greatest need. Current future efforts integrate multiomics and/or leverage single-cell technologies will us an even more fine-grained picture biology. Here, we highlight examples how high-throughput aided better LBCLs select rationally designed targeted approaches might personalize eventually improve patients' near future.